Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

247.69
+7.923.30%
Post-market: 247.690.00000.00%19:57 EDT
Volume:1.26M
Turnover:309.17M
Market Cap:16.39B
PE:19.11
High:249.01
Open:239.70
Low:237.23
Close:239.77
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:1.31
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):12.96
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:9.95
PE(LYR):-56.07

Loading ...

Ascendis Pharma Seeing 'Good Progress' in Achondroplasia Programs, Wedbush Says

MT Newswires Live
·
Aug 07

European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading

MT Newswires Live
·
Aug 06

Ascendis Pharma Posts Slide Presentation on Achondroplasia Program Updates

Reuters
·
Aug 06

Ascendis Announces Coach Week 78 Results and Provides Update on Achondroplasia Programs and Yuviwel® Uptake in the U.S.

THOMSON REUTERS
·
Aug 06

Ascendis Pharma a/S - Safety and Tolerability Remain Consistent for Monotherapy and Combination Therapy

THOMSON REUTERS
·
Aug 06

European Equities Traded in US as ADRs Advance in Tuesday Trading

MT Newswires Live
·
Aug 04

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Moderna (MRNA) and Stevanato Group (STVN)

TIPRANKS
·
Aug 03

Ascendis Pharma A/S Expected to Post Earnings of €1.38 a Share - Earnings Preview

Reuters
·
Aug 03

Ascendis Pharma is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jul 24

Ascendis Pharma (ASND) Says 104 Week TransCon CNP Data Still Looks Strong

Simply Wall St.
·
Jul 12

Ascendis Pharma Stock's Strong Momentum to Continue, Wedbush Says

MT Newswires Live
·
Jul 09

Wedbush Raises Price Target on Ascendis Pharma to $327 From $273, Keeps Outperform Rating

MT Newswires Live
·
Jul 09

Ascendis Pharma A/s : Wedbush Raises Target Price to $327 from $273

THOMSON REUTERS
·
Jul 09

Ascendis Pharma Releases Week 104 Approach Trial Radiographic Data Presentation on Transcon CNP in Achondroplasia

Reuters
·
Jul 09

European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading

MT Newswires Live
·
Jul 08

Barclays Remains a Buy on Ascendis Pharma (ASND)

TIPRANKS
·
Jul 08

Ascendis Pharma (ASND) Could Be 7% Undervalued Following Fresh ApproaCH Trial Data

Simply Wall St.
·
Jul 04

14 Value Stocks of Companies Primed for Rapid Growth Through 2028

Dow Jones
·
Jul 02

Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial

TIPRANKS
·
Jun 30

Ascendis Says Transcon CNP Achondroplasia Trial Shows Continued Leg-alignment Gains at Week 104

Reuters
·
Jun 30